NovoCure Limited Stock News

A new study published in the Journal of Clinical Investigation (JCI) finds treatment with Novocure Ltd''s (NASDAQ: NVCR ) Tumor Treating Fields (TTFields) mediated cell disruption activates the immune system and triggers an anti-tumor cell response . Preclinical research has shown that TTFields may induce a pro-inflammatory and broader immunological effect on tumor cells. Data demonstrated that treatment with TTFields directly … Full story available on Benzinga.com

NovoCure's (NVCR) CEO Asaf Danziger on Q4 2021 Results - Earnings Call Transcript

NovoCure press release (NVCR): Q4 GAAP EPS of -$0.25 misses by $0.15.Revenue of $133.21M (-7.5% Y/Y) misses by $1.28M.The company expects to achieve active patient growth between 2%…

NovoCure (NVCR) delivered earnings and revenue surprises of -150% and 1.14%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

NovoCure (NASDAQ:NVCR) is scheduled to announce Q4 earnings results on Thursday, February 24th, before market open.The consensus EPS Estimate is -$0.10 (-350.0% Y/Y) and the

They're smaller than Shiba Inu is for now. But that could change.

Healthcare is the smart play in this bear market. Here's why these three Fool.com contributors like Doximity, Amgen, and Novocure.

Healthcare is the smart play in this bear market. Here''s why these three Fool.com contributors like Doximity, Amgen, and Novocure.

Healthcare is the smart play in this bear market. Here's why these three Fool.com contributors like Doximity, Amgen, and Novocure.

NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Charles River (CRL) delivered earnings and revenue surprises of 2.89% and 1.52%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

NovoCure (NASDAQ: NVCR ) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 1 2 0 0 Last 30D 1 0 0 0 0 1M Ago 0 1 1 0 0 2M Ago 0 0 1 0 0 3M Ago 0 0 0 0 0 These 4 analysts have an average price target of $112.5 versus the current price of NovoCure at $73.88, implying upside. Below is a summary of how these 4 analysts rated NovoCure over the past 3 months. The greater the number of bullish ratings, the more positive analysts Full story available on Benzinga.com

Upgrades According to Consumer Edge Research, the prior rating for The Hain Celestial Group Inc (NASDAQ:HAIN) was changed from Equal-Weight to Overweight. For the second quarter, Hain Celestial Group

Here's why our roundtable is excited about Doximity, Novocure, and Affimed.